S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Globus Medical Stock Forecast, Price & News

-1.41 (-2.17 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $63.64
50-Day Range
MA: $63.56
52-Week Range
Now: $63.64
Volume512,458 shs
Average Volume516,923 shs
Market Capitalization$6.28 billion
P/E Ratio69.17
Dividend YieldN/A
Globus Medical, Inc., a medical device company, focuses on the development and commercialization of implants that heal patients with musculoskeletal disorders. Its spine product portfolio includes a range of implant and surgical approach options that can be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and regenerative biologic products, such as allografts and synthetic alternatives that are adjunctive treatments used in combination with stabilizing implant hardware. In addition, it provides motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous distraction devices, and interventional pain management solutions to treat vertebral compression fractures; imaging, navigation, and robotic assisted surgery technology solutions; and hip and knee joint solutions, as well as distributes human cell, tissue, and cellular and tissue based products. Further, the company offers expandable spacer products, which include RISE, RISE-L, CALIBER, CALIBER-L, ALTERA, ELSA, ELSA-ATP, SABLE, MAGNIFY, MAGNIFY-S, FORTIFY, and XPand; CREO thoracolumbar stabilization platform that offers instruments and implants for treating pathologies; CREO MIS and CREO MCS, options designed for less invasive surgery and minimal muscle disruption; CREO Derotation and CREO Rod Link Reducer systems, which help to streamline various derotation maneuvers for deformity correction; CREO Addition that provides a range of connectors; and CREO Fenestrated, a cement augmented pedicle screw system for patients with advanced stage tumors and limited life expectancy, as well as QUARTEX, an occipito-cervico-thoracic stabilization system. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.
Globus Medical logo


Overall MarketRank

1.57 out of 5 stars

Medical Sector

289th out of 1,556 stocks

Surgical & Medical Instruments Industry

29th out of 137 stocks

Analyst Opinion: 2.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment



Sales & Book Value

Annual Sales$785.37 million
Cash Flow$2.16 per share
Book Value$14.05 per share


Net Income$155.21 million


Market Cap$6.28 billion
Next Earnings Date2/18/2021 (Estimated)
-1.41 (-2.17 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GMED News and Ratings via Email

Sign-up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Globus Medical (NYSE:GMED) Frequently Asked Questions

How has Globus Medical's stock been impacted by COVID-19?

Globus Medical's stock was trading at $38.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GMED stock has increased by 67.3% and is now trading at $63.64.
View which stocks have been most impacted by COVID-19

Is Globus Medical a buy right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last twelve months. There are currently 4 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Globus Medical stock.
View analyst ratings for Globus Medical
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Globus Medical?

Wall Street analysts have given Globus Medical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Globus Medical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Globus Medical's next earnings date?

Globus Medical is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for Globus Medical

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) issued its quarterly earnings results on Wednesday, October, 28th. The medical device company reported $0.49 EPS for the quarter, beating the Zacks' consensus estimate of $0.31 by $0.18. The medical device company earned $216.10 million during the quarter, compared to analysts' expectations of $197.71 million. Globus Medical had a net margin of 12.36% and a return on equity of 9.85%.
View Globus Medical's earnings history

What price target have analysts set for GMED?

14 analysts have issued 12 month price targets for Globus Medical's stock. Their forecasts range from $53.00 to $75.00. On average, they anticipate Globus Medical's share price to reach $62.79 in the next twelve months. This suggests that the stock has a possible downside of 1.3%.
View analysts' price targets for Globus Medical
or view Wall Street analyst' top-rated stocks.

Are investors shorting Globus Medical?

Globus Medical saw a decline in short interest during the month of December. As of December 31st, there was short interest totaling 1,400,000 shares, a decline of 27.8% from the December 15th total of 1,940,000 shares. Based on an average trading volume of 608,900 shares, the days-to-cover ratio is currently 2.3 days. Currently, 1.9% of the company's stock are short sold.
View Globus Medical's Short Interest

Who are some of Globus Medical's key competitors?

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), The Trade Desk (TTD), Square (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

Who are Globus Medical's key executives?

Globus Medical's management team includes the following people:
  • Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 53, Pay $956.45k)
  • Mr. David M. Demski, CEO, Pres & Director (Age 62, Pay $1.47M)
  • Mr. Keith W. Pfeil, Sr. VP & CFO (Age 41, Pay $405.66k)
  • Ms. Kelly G. Huller, Sr. VP, Gen. Counsel & Sec. (Age 48, Pay $441.62k)
  • Mr. Daniel T. Scavilla, Exec. VP & Chief Commercial Officer (Age 55, Pay $851.28k)
  • Mr. Brian J. Kearns, Sr. VP of Bus. Devel. & Investor Relations (Age 53)
  • Mr. A. Brett Murphy, Exec. VP of International Sales (Age 55)
  • Mr. Steven M. Payne, VP & Controller (Age 49)
  • Mr. Mike Reeder, Exec. Officer
  • Mr. Richard Holifield, Exec. Officer

What is Globus Medical's stock symbol?

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Who are Globus Medical's major shareholders?

Globus Medical's stock is owned by many different retail and institutional investors. Top institutional investors include Boston Trust Walden Corp (0.51%), Gofen & Glossberg LLC IL (0.06%), Louisiana State Employees Retirement System (0.02%), State of Alaska Department of Revenue (0.01%), Symphony Financial Ltd. Co. (0.01%) and Conservest Capital Advisors Inc. (0.01%). Company insiders that own Globus Medical stock include Anthony L Williams, David D Davidar, David M Demski, James R Tobin, Kelly Huller and Robert Andrew Douglas.
View institutional ownership trends for Globus Medical

Which major investors are selling Globus Medical stock?

GMED stock was sold by a variety of institutional investors in the last quarter, including Gofen & Glossberg LLC IL, Conservest Capital Advisors Inc., and State of Alaska Department of Revenue. Company insiders that have sold Globus Medical company stock in the last year include David D Davidar, David M Demski, James R Tobin, and Kelly Huller.
View insider buying and selling activity for Globus Medical
or view top insider-selling stocks.

Which major investors are buying Globus Medical stock?

GMED stock was purchased by a variety of institutional investors in the last quarter, including 6 Meridian, Boston Trust Walden Corp, Louisiana State Employees Retirement System, and Symphony Financial Ltd. Co..
View insider buying and selling activity for Globus Medical
or or view top insider-buying stocks.

How do I buy shares of Globus Medical?

Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Globus Medical's stock price today?

One share of GMED stock can currently be purchased for approximately $63.64.

How big of a company is Globus Medical?

Globus Medical has a market capitalization of $6.28 billion and generates $785.37 million in revenue each year. The medical device company earns $155.21 million in net income (profit) each year or $1.68 on an earnings per share basis. Globus Medical employs 2,000 workers across the globe.

What is Globus Medical's official website?

The official website for Globus Medical is www.globusmedical.com.

How can I contact Globus Medical?

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.